Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection.

Justin Rheem, Vinay Sundaram, Sammy Saab

Open access · greenAbstract read

In one paragraph

Article in Gastroenterology & hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

0.8field-weighted citation impact, top 27% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study.Cureus · 2024
Article
Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct-acting antivirals.JGH open : an open access journal of gastroenterology and hepatology · 2021
Article
COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.Pharmaceutics · 2020
Review
Influential Factors of Successful Hepatitis C Treatment in Elderly Patients.Innovations in pharmacy · 2019
Article
Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.Digestive diseases and sciences · 2018
Article
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.Infection · 2018
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Justin RheemDr Rheem is a resident in the Department of Medicine at Harbor-University of California at Los Angeles Medical Center in Torrance, California. Dr Sundaram is an assistant director in the Division of Hepatology at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor in the Department of Medicine and the Department of Surgery at the University of California at Los Angeles in Los Angeles, California.

Vinay SundaramDr Rheem is a resident in the Department of Medicine at Harbor-University of California at Los Angeles Medical Center in Torrance, California. Dr Sundaram is an assistant director in the Division of Hepatology at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor in the Department of Medicine and the Department of Surgery at the University of California at Los Angeles in Los Angeles, California.

Sammy SaabDr Rheem is a resident in the Department of Medicine at Harbor-University of California at Los Angeles Medical Center in Torrance, California. Dr Sundaram is an assistant director in the Division of Hepatology at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor in the Department of Medicine and the Department of Surgery at the University of California at Los Angeles in Los Angeles, California.

Los Angeles Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of direct-acting antiviral (DAA) agents has revolutionized the treatment schema for hepatitis C virus (HCV) infection. From cure rates to tolerability, DAA agents have shown outstanding profiles compared with the prior therapy of pegylated interferon with ribavirin. However, the efficacy and safety profiles of DAA therapy in older patients, particularly the elderly, have been unclear, and patients in the 1945 to 1965 birth cohort constitute the largest proportion of the HCV population in the United States. Treating elderly patients with pegylated interferon and ribavirin has been challenging due to the frequent presence of multiple comorbidities in the elderly and high discontinuation rates caused by adverse events. Now, as more DAA agents have become widely studied and approved, subgroup analyses for the elderly population are being elucidated. Analysis of the current literature shows that these agents have been effective, well tolerated, and safe in the elderly population. This article highlights the efficacy and safety differences in interferon-based therapy and interferon-free regimens for elderly patients with HCV infection.

Indexed as

direct-acting antiviral agentselderlyepidemiologyHepatitis C virussustained viral response

Identifiers

PMID27482173

PMCPMC4962680

OpenAlexW2188099424

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.